iTi is an acronym for “identify target image,” which describes the company’s core ability to identify high‐value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. An extensively validated lead program centers on the protein target plectin, which is up-regulated on the cell surface specifically in pancreatic cancer, as well as in a growing list of malignancies. Pancreatic cancer is the fourth-deadliest cancer with a prognosis (less than 6 percent, five-year survival) that hasn’t changed in the last 40 years. Using proprietary plectin-targeting agents, multiple product opportunities have emerged addressing cancer diagnosis and therapy markets, both possessing significant unmet medical need. The plectin product suite includes an imaging agent PTP-01 (Phase 0 clinical trial) and a promising therapeutic payload delivery system.